Literature DB >> 23380999

Breast cancer: Tamoxifen--when more might be better.

Carlos Caldas1, Ian F Tannock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23380999     DOI： 10.1038/nrclinonc.2013.17

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

Authors:  H Raza Ali; Sarah-Jane Dawson; Fiona M Blows; Elena Provenzano; Samuel Leung; Torsten Nielsen; Paul D Pharoah; Carlos Caldas
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

2.  Adherence with adjuvant hormonal therapy for breast cancer.

Authors:  K J Ruddy; A H Partridge
Journal:  Ann Oncol       Date:  2009-03       Impact factor: 32.976

3.  Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.

Authors:  Bostjan Seruga; Ian F Tannock
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

Review 4.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors:  Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal:  J Natl Cancer Inst       Date:  2011-07-09       Impact factor: 13.506

5.  A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.

Authors:  Paul E Goss; James N Ingle; Silvana Martino; Nicholas J Robert; Hyman B Muss; Martine J Piccart; Monica Castiglione; Dongsheng Tu; Lois E Shepherd; Kathleen I Pritchard; Robert B Livingston; Nancy E Davidson; Larry Norton; Edith A Perez; Jeffrey S Abrams; Patrick Therasse; Michael J Palmer; Joseph L Pater
Journal:  N Engl J Med       Date:  2003-10-09       Impact factor: 91.245

6.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups.

Authors:  Christina Curtis; Sohrab P Shah; Suet-Feung Chin; Gulisa Turashvili; Oscar M Rueda; Mark J Dunning; Doug Speed; Andy G Lynch; Shamith Samarajiwa; Yinyin Yuan; Stefan Gräf; Gavin Ha; Gholamreza Haffari; Ali Bashashati; Roslin Russell; Steven McKinney; Anita Langerød; Andrew Green; Elena Provenzano; Gordon Wishart; Sarah Pinder; Peter Watson; Florian Markowetz; Leigh Murphy; Ian Ellis; Arnie Purushotham; Anne-Lise Børresen-Dale; James D Brenton; Simon Tavaré; Carlos Caldas; Samuel Aparicio
Journal:  Nature       Date:  2012-04-18       Impact factor: 49.962

7.  BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.

Authors:  S-J Dawson; N Makretsov; F M Blows; K E Driver; E Provenzano; J Le Quesne; L Baglietto; G Severi; G G Giles; C A McLean; G Callagy; A R Green; I Ellis; K Gelmon; G Turashvili; S Leung; S Aparicio; D Huntsman; C Caldas; P Pharoah
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

8.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

9.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial.

Authors:  Christina Davies; Hongchao Pan; Jon Godwin; Richard Gray; Rodrigo Arriagada; Vinod Raina; Mirta Abraham; Victor Hugo Medeiros Alencar; Atef Badran; Xavier Bonfill; Joan Bradbury; Michael Clarke; Rory Collins; Susan R Davis; Antonella Delmestri; John F Forbes; Peiman Haddad; Ming-Feng Hou; Moshe Inbar; Hussein Khaled; Joanna Kielanowska; Wing-Hong Kwan; Beela S Mathew; Indraneel Mittra; Bettina Müller; Antonio Nicolucci; Octavio Peralta; Fany Pernas; Lubos Petruzelka; Tadeusz Pienkowski; Ramachandran Radhika; Balakrishnan Rajan; Maryna T Rubach; Sera Tort; Gerard Urrútia; Miriam Valentini; Yaochen Wang; Richard Peto
Journal:  Lancet       Date:  2013-03-09       Impact factor: 79.321
  9 in total
  2 in total

1.  Personalized cancer care conference.

Authors:  Kurt S Zänker; Enrico Mihich; Hans-Peter Huber; Anne-Lise Borresen-Dale
Journal:  J Pers Med       Date:  2013-04-29

2.  Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia.

Authors:  Hannah M Jahn; Carmen V Kasakow; Andreas Helfer; Julian Michely; Alexei Verkhratsky; Hans H Maurer; Anja Scheller; Frank Kirchhoff
Journal:  Sci Rep       Date:  2018-04-12       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.